Acuta Capital Partners LLC Has $1.66 Million Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)

Acuta Capital Partners LLC lowered its position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) by 78.3% in the third quarter, Holdings Channel reports. The firm owned 46,200 shares of the company’s stock after selling 166,300 shares during the period. Dyne Therapeutics accounts for 1.3% of Acuta Capital Partners LLC’s investment portfolio, making the stock its 23rd biggest holding. Acuta Capital Partners LLC’s holdings in Dyne Therapeutics were worth $1,660,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of the company. FMR LLC raised its position in shares of Dyne Therapeutics by 69.7% during the third quarter. FMR LLC now owns 9,026,697 shares of the company’s stock worth $324,239,000 after purchasing an additional 3,707,734 shares during the period. Price T Rowe Associates Inc. MD increased its stake in Dyne Therapeutics by 8,284.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,132,092 shares of the company’s stock worth $32,141,000 after purchasing an additional 1,118,590 shares in the last quarter. Vanguard Group Inc. raised its holdings in Dyne Therapeutics by 47.7% during the 1st quarter. Vanguard Group Inc. now owns 3,440,270 shares of the company’s stock worth $97,669,000 after buying an additional 1,110,629 shares during the period. First Light Asset Management LLC lifted its stake in Dyne Therapeutics by 261.0% in the second quarter. First Light Asset Management LLC now owns 382,433 shares of the company’s stock valued at $13,496,000 after buying an additional 276,485 shares in the last quarter. Finally, Marshall Wace LLP boosted its holdings in shares of Dyne Therapeutics by 409.4% in the second quarter. Marshall Wace LLP now owns 273,567 shares of the company’s stock valued at $9,654,000 after buying an additional 219,862 shares during the period. Institutional investors own 96.68% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the stock. Stifel Nicolaus raised their price objective on shares of Dyne Therapeutics from $41.00 to $66.00 and gave the stock a “buy” rating in a report on Friday, August 16th. JPMorgan Chase & Co. lowered Dyne Therapeutics from an “overweight” rating to a “neutral” rating and cut their price target for the company from $43.00 to $35.00 in a report on Thursday, October 24th. Morgan Stanley upped their price objective on Dyne Therapeutics from $48.00 to $52.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 14th. Piper Sandler reissued an “overweight” rating and issued a $53.00 target price on shares of Dyne Therapeutics in a research report on Monday, September 23rd. Finally, Royal Bank of Canada assumed coverage on Dyne Therapeutics in a research report on Tuesday. They set an “outperform” rating and a $45.00 price target for the company. One research analyst has rated the stock with a sell rating, one has given a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Dyne Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $50.82.

Dyne Therapeutics Trading Up 6.5 %

NASDAQ DYN opened at $31.13 on Thursday. Dyne Therapeutics, Inc. has a 12 month low of $10.12 and a 12 month high of $47.45. The stock has a 50 day moving average of $31.95 and a 200-day moving average of $35.42. The company has a market cap of $3.17 billion, a PE ratio of -8.15 and a beta of 1.10.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.96) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.25). As a group, sell-side analysts predict that Dyne Therapeutics, Inc. will post -3.45 EPS for the current fiscal year.

Insider Activity at Dyne Therapeutics

In other Dyne Therapeutics news, CEO John Cox purchased 32,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 4th. The shares were acquired at an average price of $33.04 per share, for a total transaction of $1,057,280.00. Following the purchase, the chief executive officer now owns 8,000 shares in the company, valued at approximately $264,320. The trade was a -133.33 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, SVP Richard William Scalzo sold 1,390 shares of the firm’s stock in a transaction on Wednesday, September 18th. The shares were sold at an average price of $34.55, for a total value of $48,024.50. Following the sale, the senior vice president now directly owns 98,568 shares of the company’s stock, valued at $3,405,524.40. This represents a 1.39 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 176,257 shares of company stock worth $6,193,718. Insiders own 20.77% of the company’s stock.

Dyne Therapeutics Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.